Targeting Human Papillomavirus-Associated Cancer by Oncoprotein-Specific Recombinant Antibodies

Donà, Maria Gabriella; Bonito, Paola Di; Chiantore, Maria Vincenza; Amici, Carla; Accardi, Luisa

doi:10.3390/ijms22179143

Cited by 6 publications

(4 citation statements)

References 102 publications

(125 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During this time, many antibodies aimed at abolishing E6’s functions have been raised against the HPV16 E6 protein almost entirely for therapeutic purposes. Recently, anti-E6 antibodies have been reviewed focusing on their formats, therapeutic proprieties, and delivery methods (Donà et al 2021). Although some antibodies have shown therapeutic potential, the search for more efficient molecules with higher therapeutic capacity is still ongoing.…”

Section: Resultsmentioning

confidence: 99%

Targeting the Human Papillomavirus 16 E6 Oncoprotein with Antibodies

Dayer

Faulkner

Talwar

et al. 2022

Preprint

View full text Add to dashboard Cite

The human papillomavirus (HPV) 16 genome encodes two oncoproteins, E6 and E7, which are essential for viral carcinogenesis. While E7 promotes cell proliferation, E6 abolishes the resulting p53-dependent apoptotic response. Due to this specific function, E6 is considered a suitable target for the development of a variety of therapeutic agents such as antibodies. Here, we review anti-E6 antibodies/antibody fragments generated by us and others, as well as present our latest results withCamelidae-derived single-domain antibodies (sdAbs). We had previously isolated a pool of anti-E6 sdAbs to identify E6 binders with the potential to be used clinically and in research. While our previous work has focused on recombinant E6 proteins, here we evaluated these sdAbs’ binding capacity to the endogenous E6 protein using co-immunoprecipitation and immunofluorescence. We obtained reproducible results in these applications with two sdAbs, filling a gap in HPV research. Despite their apparent E6 binding ability, these sdAbs do not raise p53 levels or induce apoptosis. Thus, while these reagents are valuable diagnostic and detection tools, identifying their therapeutic potential will require further development and testing.

show abstract

Section: Resultsmentioning

confidence: 99%

Targeting the Human Papillomavirus 16 E6 Oncoprotein with Antibodies

Dayer

Faulkner

Talwar

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Oncoproteins are constitutively produced at high levels in tumor cells and are not found elsewhere in the human body, which distinguishes HPV-associated cancers [41,43]. This constitutive production makes them an excellent target for the therapeutic vaccines designed to provoke a specific antitumor response, targeting cells that express the antigens and limiting the danger of harming healthy tissue [44].…”

Section: Therapeutic Vaccines For Hpv-associated Malignanciesmentioning

confidence: 99%

Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems

et al. 2022

View full text Add to dashboard Cite

Prophylactic vaccines against human papillomavirus (HPV) have proven efficacy in those who have not been infected by the virus. However, they do not benefit patients with established tumors. Therefore, the development of therapeutic options for HPV-related malignancies is critical. Third-generation vaccines based on nucleic acids are fast and simple approaches to eliciting adaptive immune responses. However, techniques to boost immunogenicity, reduce degradation, and facilitate their capture by immune cells are frequently required. One option to overcome this constraint is to employ delivery systems that allow selective antigen absorption and help modulate the immune response. This review aimed to discuss the influence of these different systems on the response generated by nucleic acid vaccines. The results indicate that delivery systems based on lipids, polymers, and microorganisms such as yeasts can be used to ensure the stability and transport of nucleic acid vaccines to their respective protein synthesis compartments. Thus, in view of the limitations of nucleic acid-based vaccines, it is important to consider the type of delivery system to be used—due to its impact on the immune response and desired final effect.

show abstract

“…HPV potentially contributes to PCa development and chronic inflammation [5,9]. 5% of human cancers are related to HPV, and in meantime, HPV16, which is one of the most dangerous types of HPV with the highest prevalence in the world, plays a prominent role in all HPV-related cancers [10]. HPV infection is associated with some cancers, including cervix carcinomas, vulva, vagina, anal, head and neck, and penile cancers [11].…”

Section: Introductionmentioning

confidence: 99%

Frequency of Human Papilloma Virus 16/18 Patients With Prostate Cancer by Polymerase Chain Reaction Method in Hospitals of Tabriz City, Iran

Baladehi

Bazmani²,

Oskouee³

et al. 2022

J Inflamm Dis

View full text Add to dashboard Cite

Background: Prostate cancer (PCa), as the fifth leading cause of death, is the second most common cancer diagnosis in men worldwide. Human papillomavirus (HPV) can potentially contribute to PCa development and chronic inflammation. HPV infection leads to malignant and benign lesions in the genital areas of men and women. The data on the role of HPV in PCa development is contradictory. Objective: This study aims to investigate the frequency of HPV in PCa samples in hospitals in Tabriz City, Iran. Methods: This study was conducted in a cross-sectional descriptive manner. Paraffin tissue blocks including 50 patients with primary prostate adenocarcinoma and 50 patients with benign prostatic hyperplasia (BPH) were selected from Tabriz hospitals. All samples were examined for the presence of HPV16/18 by the polymerase chain reaction (PCR) method. Findings: 3 out of 50 PCa patients are infected with HPV18. None of the benign and malignant prostate samples are infected with HPV 16. Therefore, in our study, no connection exists between HPV and PCa. The Mean±SD age of HPV positive samples was 61.33±11.50 years. Conclusion: The result of this research does not support the role of HPV in the development of PCa. Therefore, additional studies are necessary to clarify the possible role of HPV in prostate carcinogenesis.

show abstract

Targeting Human Papillomavirus-Associated Cancer by Oncoprotein-Specific Recombinant Antibodies

Cited by 6 publications

References 102 publications

Targeting the Human Papillomavirus 16 E6 Oncoprotein with Antibodies

Targeting the Human Papillomavirus 16 E6 Oncoprotein with Antibodies

Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems

Frequency of Human Papilloma Virus 16/18 Patients With Prostate Cancer by Polymerase Chain Reaction Method in Hospitals of Tabriz City, Iran

Contact Info

Product

Resources

About